-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Biology and Translation of NK Cells

PhD Trainee
Program: Scientific Symposia
Hematology Disease Topics & Pathways:
Fundamental Science, Research, Biological therapies, Bispecific Antibody Therapy, Translational Research, Combination therapy, drug development, immunology, Therapies, Immunotherapy, Biological Processes, Natural Killer (NK) Cell Therapies
Saturday, December 10, 2022: 2:00 PM-3:15 PM
293-294 (Ernest N. Morial Convention Center)
Katy Rezvani, MD, The University of Texas M D Anderson Cancer Center
No relevant conflicts of interest to declare.
Cellular immunotherapy has revolutionized our approach to managing cancer, giving hope to patients with otherwise limited prognosis and survival. The use of chimeric antigen receptor (CAR) T cells has been at the forefront of recent advances in cancer immunotherapy. CAR T cells have been mostly effective in B cell malignancies and their use is associated with major toxicities including cytokine release syndrome (CRS), neurotoxicity, and the potential for causing graft versus host disease (GVHD) with allogeneic products. Natural Killer (NK) cells have an intrinsic propensity to target malignant cells, which can be further enhanced by activating them with cytokines to induce a memory-like phenotype and/or by arming them with novel CAR constructs. Cytokine-engineered and CAR-armed NK cells have demonstrated excellent safety with promising efficacy signal in recent clinical trials, making them attractive alternatives to T cell-based approaches. Recently CRISPR-based gene-editing techniques have been successfully applied to NK cells to further enhance their anti-tumor responses. Furthermore, novel NK cell engagers have shown promising activity in preclinical and early phase clinical trials. Based on these major recent advances we believe that the hematology community will benefit from a symposium highlighting the basic biology and translation of the NK cell-based therapies to the clinic. This proposal is supported by the Subcommittee on Emerging Gene & Cell Therapies.

Rizwan Romee, MD

Dana-Farber Cancer Institute, Boston, MA

Eric Vivier, DVM, Phd, vivier@ciml.univ-mrs.fr

Centre d'Immunologie de Marseille-Luminy (CIML), Marseille, France

Jeffrey S. Miller, MD, MD

Masonic Cancer Center, University of Minnesota, Minneapolis, MN

See more of: Scientific Symposia